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Intervention(s), exposure(s)
Initiate, continue, or change ART regimen during pregnancy, for any duration (short-course prophylaxis, cART).
Comparator(s)/ control
Not applicable.
Context
Studies on values and preferences after the first recommendation for ART drugs for preventing vertical transmission in 2000.
Outcome(s)
Primary outcomes Quantitative measurements of values and preferences (standard gamble, time trade off, visual analogue scale, willingness to pay, conjoint analysis, discrete choice, contingent choice method, pairwise comparison, ranking, probability trade off, direct choice), and qualitative measurements of values and preferences (studies that inform on preferences, views, experiences, attitudes, or perceptions). The results of this study will be used to inform a guideline on different ART regimens for pregnant women. Thus, values and preferences related to maternal health (mortality, adverse effects, AIDSrelated illness, viral load suppression, treatment interruptions/gaps or switch of ART, hepatitis B resistance) and child health (neonatal mortality or stillbirth, mortality at 1 year, preterm delivery [<37 weeks], early preterm delivery [<34 weeks], birth weight [low birth weight], head circumference [small head circumference], HIV infection, hepatitis B infection, long-term child development, adverse effects) will be of particular importance. However due to the exploratory nature of the study, outcomes of interest will not be limited to specifics and we expect that we will need to infer values and preferences specific to our outcomes from evidence of related outcomes. The review's aim is to inform a clinical practice guideline regarding two ART regimens.
Secondary outcomes
None.
Data extraction, (selection and coding)
Two reviewers will independently extract data using a standardized form in Microsoft Excel. Data from qualitative studies, in the form of quotations and descriptions of findings in results sections and abstracts, will be extracted using thematic synthesis. Barriers and facilitators related to ART choice will be extracted, including patient-reported reasons for compliance. Data from components of mixed-methods studies will only be extracted if they satisfy inclusion criteria. Disagreements will be resolved through discussion and consensus, or by consulting a third party if necessary. The following details will be extracted: first author, publication year, number of participants, participant demographics (e.g. age, length of time living with HIV, whether they have previously or are currently taking ART and what regimen, current and previous pregnancies, availability of treatment [e.g. government funded program, private insurance/benefits, clinical trial], and other data as provided such as drug use, sexual orientation, whether they are sex workers, disabilities, coinfections, experience of violence, history of mental health issues, etc.), methods used to extract data (e.g. standard gamble, survey techniques, semi-structured interview), and values and preferences outcomes.
Risk of bias (quality) assessment
To asses quality, we will use the Newcastle Ottawa Scale for observational studies, and the CASP tool for qualitative studies. For randomized controlled trials, we will use the Cochrane Collaboration risk of bias tool to assess the risk of bias.
Strategy for data synthesis
For quantitative measures (e.g. utilities and health status values), we will pool studies to generate an estimate and associated 95% confidence intervals using the inverse variance method (random effect model) in ReviewManager software. For qualitative measures, reviewers will categorize codes from extracted data to build descriptive themes.
Analysis of subgroups or subsets
None planned.
Dissemination plans
We will submit this systematic review to peer-review journals for publication. This review will inform guidelines on the use of therapies for women living with HIV who are pregnant or considering pregnancy. We will share our findings through national and/or international conferences and workshops.
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